Genocea Biosciences Inc · OTC:GNCAQ
Genocea Biosciences — Investor Presentation (January 2020)
29 slides from Genocea Biosciences's investor presentation, Jan 13, 2020
Slide 1: Next generation cancer immunotherapies
Next generation cancer immunotherapies 1
Slide 2: Forward-looking statements disclaimer
This presentation contains “forward-looking” statements that are within the meaning of federal securities laws and are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements include information concerning our possible or ass
Slide 3: Why Genocea?
Why Genocea? Revolutionary antigen discovery platform TARGETS MATTER PROPRIETARY PLATFORM GEN-009 GEN-011 Two differentiated, clinical stage programs Neoantigen Neoantigen vaccine cell therapy 2Q 2020 IND Significant near-term, Mid 2020 1H 2021 value-creating initial clinical data milestones initial
Slide 4: Corporate Overview
CORPORATE OVERVIEW Developing cancer therapies by unlocking the targets that matter most Proprietary platform that selects antigens enabling powerful anti-tumor immune responses Uniquely profiles tumor Avoids potential barriers to efficacy Selects the therapeutically and T cell repertoire + = releva
Slide 5: Antigen Selection Drives Next Generation of IO Therapies
Antigen Selection Drives Next Generation of IO Therapies Lessons from the IO Revolution: • Patient T cells can be unleashed to kill tumors • T cells that kill tumors attack neoantigens (tumor mutations that are often individualized) Opportunities: • ICI: improve response rates by amplifying anti- tu
Slide 6: Antigen Selection: Our Critical Differentiator
Antigen Selection: Our Critical Differentiator Uniquely identifying therapeutically relevant neoantigens Relevant both to tumor and patient immune system (surface-expressed and immunogenic) Groups antigens according to T cell responses (anti-tumor, TARGETS MATTER pro-tumor, or irrelevant) Comprehens
Slide 7: Profiling Both T cell and Tumor Essential to Antigen Selection
Profiling Both T cell and Tumor Essential to Antigen Selection ATLAS: Antigens eliciting anti- tumor T cell responses Identifies T cell antigens relevant to Surface peptides recognized by both tumor T cells Relevance T cell receptor and immune Candidate antigen system – by design MHC molecule Surfac
Slide 8: Profiles Patients' Tumor-specific T cell Repertoire
Profiles Patients’ Tumor-specific T cell Repertoire For every candidate antigen: Tumor NGS analysis Unique Bacterial vectors sample plasmids expressing each Autologous candidate antigen dendritic cell • Multiplexed cytokine readout • Identifies CD4+ and CD8+ T cell Activation/ RESPONSE responses Sup
Slide 9: ATLAS Selects for Neoantigens that Drive Clinically Relevant Immune Responses
ATLAS Selects for Neoantigens that Drive Clinically Relevant Immune Responses Example: NSCLC patient; 52 mutations identified and profiled; IFNγ responses depicted CD8+ T cells CD4+ T cells Neoantigens – selected for therapy Not neoantigens – background-like responses Inhibitory neoantigens (inhibig
Slide 10: Inclusion of Inhibigens Can Reverse Efficacy of a Protective Therapy
IMPORTANT POTENTIAL IMPLICATIONS OF INHIBITORY RESPONSES Inclusion of Inhibigens Can Reverse Efficacy of a Protective Therapy Therapeutic vaccination with the Therapeutic vaccination with a The presence of inhibigens in an ATLAS-identified S10 neoantigen pool of ATLAS-identified otherwise protective
Slide 11: Clinical Data Suggest ICI Failure May Be Influenced by Inhibigens
IMPORTANT POTENTIAL IMPLICATIONS OF INHIBITORY RESPONSES Clinical Data Suggest ICI Failure May Be Influenced by Inhibigens 70% 60% 50% Non-responder Responder 40% Circle size represents tumor 30% mutational burden (TMB) % Stimulatory % 20% 10% 0% 0% 5% 10% 15% 20% 25% % Inhibitory Pre-treatment ATLA
Slide 12: ATLAS Enables Next Generation Immunotherapies
ATLAS Enables Next Generation Immunotherapies Tailored to tumor and immune system • Neoantigens must be expressed by tumor and be immunogenic Next Generation IO Drive anti-tumor responses • Include neoantigens of CD4+ and CD8+ T cell • GEN-009: neoantigen responses vaccine • Rule out inhibigens • GE
Slide 13: Drives Emerging Immunotherapy Pipeline
Drives Emerging Immunotherapy Pipeline Discovery Pre- IND Phase 1/2a Pivotal Status & Anticipated Milestones GEN-009 - Neoantigen vaccine • Pioneering immunogenicity: ASCO 2019 Top 10 IO study • Initial clinical data in mid 2020 GEN-011 - Neoantigen T cell therapy • IND in 2Q 2020 • Initial clinical
Slide 14: GEN-009 Generating unprecedented immune responses
GEN- 009 Generating unprecedented Neoantigen immune responses Vaccine 14
Slide 15: GEN-009 Optimized Neoantigen Vaccine
GEN- 009 Optimized Neoantigen Vaccine 15
Slide 16: GEN-009 Phase 1/2a Trial Part A
GEN- 009 Phase 1/2a Trial Part A • Vaccine monotherapy • Patient cohort: no evidence of disease • Multiple tumor types with ICI approval • Objectives: safety, immunogenicity • Status: all patients in follow-up • Vaccine well-tolerated • No disease progression in vaccinated patients • Highly immunoge
Slide 17: Enables Unparalleled Vaccine Immune Responses
Enables Unparalleled Vaccine Immune Responses Frequency % neoantigens with immune responses 60% 99% Potential Patient Benefits Response breadth to prevent tumor escape Best Peer Results1 GEN-0092 Achieved in Monotherapy combination with ICI 1 Sahin, et al., Nature 2017 (N=8); Ott, et al., Nature 201
Slide 18: Enables Unparalleled Vaccine Immune Responses: Effector function and memory
Enables Unparalleled Vaccine Immune Responses Effector function Central memory response (ex vivo assay) (IVS assay) CD4+ CD8+ CD4+ CD8+ 87% 51% Best peer 41% results 1 57% 57% 23% GEN-0092 17% 0% Potential Patient Benefits Potential Patient Benefits Rapid tumor killing Durable efficacy 1 As monother
Slide 19: GEN-009 Phase 1/2a Trial Part B in ICI Patients
GEN- 009 Phase 1/2a Trial Designed to Showcase Vaccine Benefits in ICI Patients Part B • Combination of GEN-009 and standard-of-care PD-1 based regimen intended in cohorts of patients with advanced disease • Vaccination contribution to be determined after ICI response established • Objectives: safet
Slide 20: GEN-011 Neoantigen T cell Therapy
GEN- 011 Potential first-in-class solid Neoantigen tumor T cell therapy T cell Therapy 20
Slide 21: TIL Therapy Has Changed the Narrative for Solid Tumor T cell Therapy
TIL Therapy Has Changed the Narrative for Solid Tumor T cell Therapy Tumor infiltrating lymphocyte (TIL) therapy has delivered durable efficacy in hard-to- treat solid tumor patients • 44% ORR in late-stage cervical cancer patients • Similar benefits in heavily pretreated metastatic melanoma patient
Slide 22: Lessons Learned from TIL Therapy
Lessons Learned from TIL Therapy Multiple CD4+ and CD8+ neoantigen targets T cells • Attacks tumor • CD4+ T cells support heterogeneity, limits activity and CD4+ CD8+ tumor escape persistence of CD8+ T cells and both can directly kill tumor cells Diversity of TCRs per Patient safety target neoantige
Slide 23: Still Significant Opportunities to Enhance T cell Therapy for Solid Tumors
Still Significant Opportunities to Enhance T cell Therapy for Solid Tumors Approaches to Address Increase target breadth & specificity TILs only target a limited proportion of neoantigens Neoantigen selection via Avoid deleterious T cell responses Inhibitory, pro- tumor responses to neoantigens shou
Slide 24: GEN-011 ATLAS-Enabled T cell Therapy for Solid Tumors
GEN- 011 ATLAS-Enabled T cell Therapy for Solid Tumors Autologous T cell therapy T cells expanded from peripheral blood: • Both CD4+ and CD8+ T cells with validated antigen responses • Multiple specificities for broader coverage, reduced potential for metastatic escape • HLA agnostic • Ability to ad
Slide 25: GEN-011 Next Generation Neoantigen Adoptive Cell Therapy
GEN- 011 Next Generation Neoantigen Adoptive Cell Therapy Collect tumor and ATLAS to select Expand and sort Administer GEN-011 blood samples, neoantigens of pre- neoantigen-specific to patient sequence exome existing CD4+ and T cells CD8+ T cell responses Exclude inhibigens 25
Slide 26: Phase 1/2 Pilot Study in Refractory Tumors
Phase 1/2 Pilot Study in Refractory Tumors Evaluating Low and High Dose Therapy Tumors responsive to immunotherapy without available disease control Melanoma, NSCLC, SCCHN, Urothelial, RCC Cohort A: Multiple Low Dose N=6-12 patients Trial Objectives No lymphodepletion Up to 5 doses of 2 x 108 cells
Slide 27: GEN-011 Product has Desired Functional Properties
In Scale Development Runs, the GEN-011 Product has Desired Functional Properties Most T cells in the final product are specific for Cells are functionally cytolytic in ATLAS-defined neoantigens an in vitro killing assay Control Antigen-specific 100 Specific Neoantigens 70% 80 5% Unpulsed Control 60
Slide 28: Why Genocea?
Why Genocea? Revolutionary antigen discovery platform TARGETS MATTER PROPRIETARY PLATFORM GEN-009 GEN-011 Two differentiated, clinical stage programs Neoantigen Neoantigen vaccine cell therapy 2Q 2020 IND Significant near-term, Mid 2020 1H 2021 value-creating initial clinical data milestones initial
Slide 29: Genocea contact details
NASDAQ: GNCA 100 Acorn Park Drive Cambridge, MA 02140 USA +1 617.876.8191 www.genocea.com29
Genocea Biosciences — Investor Presentation (January 2020) on 6ix